This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2007 Apr;105(1):3-6.

doi: 10.1016/j.ygyno.2007.01.038.

What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?

Ernest S Han, Bradley J Monk

PMID: 17383545
DOI: 10.1016/j.ygyno.2007.01.038

Editorial

What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?

Ernest S Han et al. Gynecol Oncol. 2007 Apr.

. 2007 Apr;105(1):3-6.

doi: 10.1016/j.ygyno.2007.01.038.

Authors

Ernest S Han, Bradley J Monk

PMID: 17383545
DOI: 10.1016/j.ygyno.2007.01.038

No abstract available

PubMed Disclaimer

Similar articles

Bevacizumab in the treatment of ovarian cancer.
Han ES, Monk BJ. Han ES, et al. Expert Rev Anticancer Ther. 2007 Oct;7(10):1339-45. doi: 10.1586/14737140.7.10.1339. Expert Rev Anticancer Ther. 2007. PMID: 17944559 Review.
Pulmonary hypertension in two patients treated with bevacizumab for recurrent ovarian cancer.
Liotta M, Rose PG, Escobar PF. Liotta M, et al. Gynecol Oncol. 2009 Nov;115(2):308-9. doi: 10.1016/j.ygyno.2009.08.003. Epub 2009 Sep 8. Gynecol Oncol. 2009. PMID: 19740533 No abstract available.
Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?
Richardson DL, Backes FJ, Hurt JD, Seamon LG, Copeland LJ, Fowler JM, Cohn DE, O'Malley DM. Richardson DL, et al. Gynecol Oncol. 2010 Jul;118(1):47-51. doi: 10.1016/j.ygyno.2010.01.011. Epub 2010 Apr 10. Gynecol Oncol. 2010. PMID: 20382413
[Surgical management of bevacizumab-associated peritonitis due to perforation].
Kube R, Meyer F, Bien N, Schmidt C, Mroczkowski P, Dalicho S, Lippert H. Kube R, et al. Zentralbl Chir. 2009 Sep;134(5):462-7. doi: 10.1055/s-0028-1098701. Epub 2009 Sep 15. Zentralbl Chir. 2009. PMID: 19757347 German.
Bevacizumab toxicities and their management in ovarian cancer.
Randall LM, Monk BJ. Randall LM, et al. Gynecol Oncol. 2010 Jun;117(3):497-504. doi: 10.1016/j.ygyno.2010.02.021. Epub 2010 Apr 2. Gynecol Oncol. 2010. PMID: 20363017 Free PMC article. Review.

See all similar articles

Cited by

Beyond chemotherapy: targeted therapies in ovarian cancer.
Yap TA, Carden CP, Kaye SB. Yap TA, et al. Nat Rev Cancer. 2009 Mar;9(3):167-81. doi: 10.1038/nrc2583. Nat Rev Cancer. 2009. PMID: 19238149 Review.
Bowel perforation in non-small cell lung cancer after bevacizumab therapy.
Schellhaas E, Loddenkemper C, Schmittel A, Buhr HJ, Pohlen U. Schellhaas E, et al. Invest New Drugs. 2009 Apr;27(2):184-7. doi: 10.1007/s10637-008-9162-z. Epub 2008 Jul 30. Invest New Drugs. 2009. PMID: 18665327
Therapeutic advances in women's cancers.
Carroll AR, Coleman RL, Sood AK. Carroll AR, et al. Front Biosci (Schol Ed). 2011 Jan 1;3(1):82-97. doi: 10.2741/s134. Front Biosci (Schol Ed). 2011. PMID: 21196359 Free PMC article. Review.
Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups.
Qi WX, Shen Z, Tang LN, Yao Y. Qi WX, et al. Eur J Clin Pharmacol. 2014 Aug;70(8):893-906. doi: 10.1007/s00228-014-1687-9. Epub 2014 May 27. Eur J Clin Pharmacol. 2014. PMID: 24858820
Recognizing the toxicity of "nontoxic" drugs employed in the management of malignant disease.
Markman M. Markman M. Curr Oncol Rep. 2007 Sep;9(5):329-30. doi: 10.1007/s11912-007-0041-0. Curr Oncol Rep. 2007. PMID: 17706158 No abstract available.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science